Amgen Inc. has reported that the bone drug Xgeva (denosumab) has the advantage of delaying time to symptomatic bone metastases, according to a post hoc analysis in a Phase III trial of castrate resistant prostate cancer patients. But it remains to be seen whether the result will one day be accepted by FDA and incorporated into the product's labeling. Denosumab has been available for postmenopausal osteoporosis since mid-2010 under the brand name Prolia and was cleared for prevention of skeletal related...